> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sweetling Health and Aviva Bio win HLTH’s women’s health pitch competition
- URL: https://www.healthdatacon.io/articles/hlth-womens-health-pitch-sweetling-aviva-winners/
- Published: 2026-11-17T02:10:00.000Z
- Updated: 2026-11-17T06:44:05.000Z
- Description: Judges gave the digital health award to Sweetling Health and the life sciences award to Aviva Bio, chosen from nine founders on the Revv Stage.
- Author: HDM Staff
- Tags: Patient Care, Americas, HLTH

LAS VEGAS — HLTH’s women’s health pitch judges divided the prize into digital health and life sciences Monday, selecting Sweetling Health for a text-based maternal monitoring service and Aviva Bio for its proposal to develop a testosterone treatment for women. The two winners were chosen from nine finalists at the Revv Stage competition.

HLTH content lead Alexa McHale emceed the [pitch competition](https://hlth.com/events/usa/agenda/2026/womens-health-pitch-competition?ref=healthdatacon.io). The judges were Springbank Collective founding partner Elana Berkowitz, Amboy Street Ventures partner Colleen Foster and Emmeline Ventures co-founder and general partner La Keisha Landrum Pierre. Each founder gave a short presentation and took questions from the judges.

## A text message instead of another app

Sweetling Health co-founder and CEO Gwendolyn Rahn said her company wanted to provide a “digital safety net” for women in areas with limited maternity care. She said it was “delivered entirely via text,” a design choice she tied to reaching patients who may be unlikely to download another app, use a portal or buy a wearable.

Rahn described proactive check-ins during pregnancy and through 12 months postpartum. The company screens for risks between visits and adjusts how often it checks in. An [Indiana rural health resource](https://www.in.gov/grow-rural-health/resources/?ref=healthdatacon.io) describes the service as remote monitoring that rural hospitals and other clinics can use without issuing a device. It lists screening across physical, mental and social health concerns.

Judges cited the focus on rural maternal health and the speed at which the business had grown since coming to market. Those were reasons for the award, which did not establish that monitoring reduces complications. The approach depends on patients responding to messages and a clinical team being able to act when a report signals risk. The pitch’s operational question was how to reach people between appointments and connect what they say to a team that can respond.

## Aviva’s proposed testosterone treatment

Jessica Halem, co-founder and head of business development at Aviva Bio, pitched a treatment designed for a problem she described in the context of menopause and low libido. “There is a safety concern,” she said when discussing conventional testosterone. Her description of the development goal was to “solve for safety and keep the benefits.”

Aviva is developing a non-aromatizing testosterone candidate, which the team argues could preserve the intended effect while addressing one potential source of concern. Its description in another [2026 finalist listing](https://wplatform.co/insights/meet-the-finalists-whw-usa-2026?ref=healthdatacon.io) similarly identifies an investigational approach. The team’s case for the design should be distinguished from evidence about how the candidate performs in patients.

The judges put that pitch in the life-sciences category and Sweetling in digital health. The split reflected a practical difference in the questions facing the two companies. Aviva will have to establish safety and efficacy for its candidate. Sweetling has to show that a text-based service can recognize concerns and support follow-up across the kinds of providers and communities it hopes to serve.

## Seven other approaches to care and drug development

Mehek Bapna, founder and CEO of Tessering Biosciences, pitched a “birth control pill without hormones” intended to be taken “once a week.” She described the project as an effort to improve on earlier compounds and address the difficulty some patients have following a daily regimen. The proposed schedule was a development objective she described to the audience.

Juliana Di Simone, founder and CEO of Forela, called herself “patient zero” and described how it had taken years to identify her endometriosis. She said Forela seeks to bring a “multidisciplinary approach” into clinical visits, with technology designed to draw on several specialty perspectives before the appointment. Her pitch centered on coordination when a patient otherwise has to move between specialists herself.

Dr. Maria Uloko, founder and CEO of VULVAi, proposed “AI infrastructure” for “women’s pelvic health.” She cited her experience building a vulvar clinic with a lengthy waiting list. Her pitch took the demand at a specialty clinic as a starting point for expanding how patients and other clinicians find relevant expertise.

Jennifer Voss, co-founder and CEO of LERA Health, said the company would combine “biomarkers, symptoms and lifestyle” to guide care and use an “in-app coach” alongside its clinical team. She described a model intended to get to know patients over time and said the company sees digital health platforms, employers and health systems as potential partners.

Nicole Lykens, co-founder and CTO of Valaya Bio, pitched an investigational “RNA medicine” for neurodegenerative disease. She described a “master switch” as the team’s term for the biological target behind its approach. The examples she cited from samples, cells and animals were part of the case for further development, before evidence of a benefit in patients.

Ines Knežević, co-founder of Megi Health, described using “community health workers” and a “clinically guided AI platform” to identify concerns and help coordinate care during pregnancy. She said the platform was designed to help teams use information from conversations to decide who needs escalation, drawing on the company’s experience deploying technology in another care setting.

Dr. Yaneve Fonge, founder and CEO of Upsidian, said “the doula is the focus” of a service designed to make doula care more accessible to families. She described “AI assisted navigation between visits” and tools that help doulas with work such as scheduling, enrollment and billing. She said the company was starting in Minnesota.

Three of the digital pitches made the differences in delivery particularly clear. Sweetling described checking in directly with the patient, Megi described equipping people already working with a patient, and Upsidian described helping families find a doula and helping that doula manage the work of providing care. Each targets a different gap in the chain from contact to follow-up. The judges’ decision favored the company that put rural reach at the center of its pitch.

The format gave each startup time to explain why its intervention might reach patients and time for the judges to challenge it. The work ahead varies by approach. For tools meant to operate between visits, the question is how reliably an alert reaches someone who can help. For investigational drugs, it is whether the proposed benefits and risks hold up through studies and review. The awards recognized two pitches at different points along those paths.